FDA ONP Leadership On Switches Could Benefit Chronic Therapies
This article was originally published in The Tan Sheet
Executive Summary
The recent elevation of FDA's OTC drug division to office status sets the stage for the unit to take a more prominent role in evaluating Rx-to-OTC switches for chronic conditions
You may also be interested in...
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands